Varda Space raised $187M to build pharma's first orbital factory — and it's hiring 19 people a week

A $187M round reshapes the orbital pharma race

Varda Space Industries closed a $187 million Series C round on July 10, 2025, bringing the El Segundo-based startup's total capital raised to $329 million, CNBC reported. Natural Capital and Shrug Capital led the round, with participation from Founders Fund, Peter Thiel, Khosla Ventures, Caffeinated Capital, Lux Capital, and Also Capital.

That figure puts Varda in a different category from most space startups. The company has now raised more than double what it pulled in across its earlier rounds combined (the Series B in April 2024 was $90 million, and the company had raised $145 million total before this latest close). Lux Capital and Founders Fund have backed Varda since its seed stage in 2020, while Caffeinated Capital led the Series B and returned for the C.

CEO Will Bruey told CNBC's Morgan Brennan the capital serves two purposes. First, flight cadence: more launches, more often. Varda had completed three successful launch-and-return missions by the time the Series C closed, with a fourth in orbit and a fifth expected before the end of 2025. The company's stated target is eventually moving to a monthly launch cadence. Second, the biologics lab. Varda opened a new 10,000-square-foot laboratory in El Segundo that will let its pharmaceutical scientists begin developing processes to crystallize biologics like monoclonal antibodies, a market estimated at $210.06 billion as of 2022.

Chief Science Officer Adrian Radocea framed the lab expansion as a bet on the broader thesis: "Our new lab space is an investment in our belief that in-space pharmaceutical manufacturing will drive the foundation of the orbital economy." Ravi Tanuku, general partner at Natural Capital and a Varda board member, pointed to the company's government hypersonic-testbed work — the W-series capsules hit Mach 25 on reentry — as evidence that Varda has already proven repeatable orbital-reentry capability and attracted serious defense demand before turning that momentum toward pharmaceutical scale.

CB Insights data puts Varda's 2024 revenue at $48 million, a figure that likely reflects government hypersonic-testing contracts and early pharma partnership work rather than commercial drug sales. The company is still pre-revenue on its core pharmaceutical thesis (no microgravity-manufactured drug has reached the market yet). The Series C is a bet that the technical foundation (six missions, six reentries, autonomous navigation, thermal protection) is solid enough to justify scaling the science and engineering teams that would turn orbital crystallization into a repeatable industrial process.

Zero G Talent's board lists 19 Varda roles added in the past week alone, spanning space mission operations, embedded software, controls and automation, and ground systems engineering, with salary ranges from $120,000 to $216,000. The company now has offices in El Segundo, Huntsville, Alabama, and Washington, D.C., and a headcount that has grown from 90-plus employees at the time of the Series B to a workforce scaling fast enough to justify a nine-figure raise.

What the sixth reentry proved

Varda Space Industries launched its W-6 capsule on March 30, 2026, aboard SpaceX's Transporter-16 rideshare. It was the company's sixth mission overall and its second reentry of the year. The capsule landed safely at the Koonibba Test Range in South Australia, operated by Southern Launch, completing a flight that carried three government-backed payloads through hypersonic conditions no ground facility can replicate.

The mission matters because it proves Varda's reentry platform works as repeatable infrastructure, not a one-off experiment. Every W-series capsule has used a heatshield made from C-PICA (Conformal Phenolic Impregnated Carbon Ablator), a material originally developed at NASA's Ames Research Center and manufactured at Varda's El Segundo headquarters. On W-6, two of those tiles were produced at Ames using an alternative technique called "eChar," giving NASA a direct comparison dataset between production methods during the same reentry.

The bigger technical step was the navigation payload. W-6 carried an autonomous navigation system from Rhea Space Activity, funded through the Space Force and the Air Force Research Laboratory. The system, called AutoNav, uses onboard imagery to identify stars and low Earth orbit satellites and determine the vehicle's position without GPS or radio contact. That capability solves a specific problem: during hypersonic reentry, the plasma sheath around the vehicle blocks radio signals. Elliott M. Sanders, National Security Coordinator at Rhea Space Activity, called celestial navigation through the plasma sheath "a reliable way to navigate during GPS and radio blackout periods."

AutoNav traces back to code developed for NASA's Deep Impact program, where it guided a projectile into a comet at 22,000 miles per hour. Adapting that algorithm for a reentry capsule moving through the same plasma environment is the kind of cross-program reuse that lowers development risk.

The third payload was a nose tile from Sandia National Laboratory embedded with small samples of advanced thermal protection materials. Sensors recorded temperatures during reentry so researchers could compare real-world data against computer model predictions. Dave McFarland, Varda's Vice President of Hypersonic Test and Targets, said the data from this single mission "would have taken years to collect through traditional testing methods."

The Prometheus program — an AFRL partnership with commercial space entities designed to accelerate hypersonic technology testing at low cost and high cadence — funded W-6. That funding model, government payloads riding on commercially operated reentry vehicles, is what lets Varda fly often enough to build a manufacturing cadence rather than a test program.

For the pharmaceutical work Varda is known for, the implication is direct. Reliable, frequent reentry is the bottleneck for returning manufactured biologics from orbit. Six successful missions with a standardized capsule and heatshield system means the return leg is no longer the riskiest part of the process. The company is scaling vehicle production in El Segundo to match the 2026 cadence increase, and the navigation data from W-6 feeds into making each successive reentry more autonomous and less dependent on ground tracking.

The technical foundation is in place. The question now is what Varda builds on top of it.

Inside the El Segundo crystallization lab

Varda's new 10,000-square-foot lab in El Segundo is where the company decides which drugs are worth launching into orbit. The facility, announced alongside the Series C round, is designed to do the ground-level process engineering that precedes every orbital mission: identifying which biologics, primarily monoclonal antibodies and recombinant proteins, respond well to microgravity crystallization and under what conditions.

Monoclonal antibodies are a $210 billion market, but crystallizing them at scale is difficult on Earth. The molecules are large, structurally flexible, and prone to aggregation under gravity-driven convection and sedimentation. In microgravity, those forces disappear. Supersaturation becomes more uniform, transport is diffusion-driven, and the resulting crystal structures can be more ordered, more stable, and more soluble. That can mean a drug that currently requires intravenous infusion becomes a shelf-stable subcutaneous injection, or a formulation with higher bioavailability at a lower dose.

Varda's pharmaceutical scientists use the El Segundo lab to run crystallization experiments across a range of temperatures, buffer conditions, and gravity levels before committing a molecule to an orbital mission. The company operates a hypergravity crystallization platform, a large-diameter centrifuge that modulates gravity from 1g to 5g, letting researchers screen candidates and verify that a given biologic will behave predictably in zero-g. The goal is to arrive at orbit with a process already defined, so the bioreactor onboard the W-series capsule executes a known recipe rather than conducting open-ended experiments mid-flight.

The lab also serves as the hiring hub for Varda's pharmaceutical team. The company has brought in structural biologists and crystallization scientists with prior experience at large pharmaceutical firms, and the El Segundo facility is where that team works. Varda's job board lists multiple controls and automation software engineer roles based in El Segundo, which signals that the lab is building out automated crystallization screening and process control systems, not just manual benchwork.

The Series C capital funds both the lab buildout and the increase in flight cadence needed to hit the turnaround times pharmaceutical companies expect. Varda completed three successful orbital missions by mid-2025, with a fourth in orbit and a fifth planned before year-end. The lab's purpose is to feed that pipeline with validated candidates, turning what was once a bespoke research experiment into a repeatable manufacturing service.

Why Huntsville?

Varda opened an office in Huntsville, Alabama, joining its El Segundo headquarters and Washington, D.C. presence, a geography choice that looks counterintuitive for a pharmaceutical manufacturing startup until you map it against the company's dual-use business model.

The Huntsville office sits at 1300 Enterprise Way, inside the same defense-and-aerospace corridor that houses NASA's Marshall Space Flight Center and Redstone Arsenal. Varda's own description of the Huntsville operation is blunt about the intent: the company provides "a commercial reentry vehicle solution" and is "the most relevant and rapid option for flight testing in high hypersonic conditions supporting our customers local to Redstone Arsenal." That phrasing — "customers local to Redstone Arsenal" — is the giveaway. Varda's government hypersonic testbed business, which uses its W-series capsules to validate thermal protection materials, navigation systems, and sensors at Mach 25 during reentry, depends on proximity to the Army and Defense Department installations concentrated in Huntsville.

But the Huntsville hire also serves the pharma side. The company's job board shows open roles tagged to Huntsville that include pharmaceutical scientists, bridging the gap between the orbital manufacturing platform and the downstream biologics work happening in El Segundo. Huntsville has a deep bench of aerospace engineers, propulsion technicians, and systems integration specialists who already hold security clearances and understand hardware-in-the-loop testing at scale, exactly the workforce Varda needs to increase flight cadence for its orbital pharmaceutical missions.

The location also gives Varda a recruiting lane into NASA Marshall's materials science and space manufacturing research community, which has decades of experience in microgravity processing and crystal growth. When Bruey said the Series C capital would "continue to increase our flight cadence," the Huntsville office is part of how that translates into headcount, pulling from a labor market that blends defense hypersonic engineering with the kind of precision manufacturing culture that pharmaceutical-grade hardware demands.

The split tells you how Varda sees its own future: El Segundo runs the science (monoclonal antibody crystallization, biologics formulation, analytical sciences). Huntsville runs the platform (reentry vehicles, hypersonic testing, government payloads). One location manufactures the drug. The other makes sure the capsule survives the trip home.

United Therapeutics signs on

On May 13, 2026, Varda announced its first major pharmaceutical partnership: a collaboration with United Therapeutics Corporation (Nasdaq: UTHR) to develop improved formulations of small-molecule treatments for rare pulmonary disease aboard Varda's orbital manufacturing platform. The deal is the first to focus on space-based drug formulation intended to produce actual therapies for patients, not just proof-of-concept experiments.

On Earth, sedimentation and convection currents disrupt how molecules assemble during crystallization, often producing irregular crystal structures that limit a drug's performance. In microgravity, those forces disappear. Molecules assemble more slowly and uniformly into highly ordered structures that are difficult or impossible to produce on the ground. The companies will process small-molecule pulmonary disease medicines across multiple low-Earth-orbit missions, using Varda's W-series reentry capsules to return finished products to Earth. The stated goal is novel polymorphs with better bioavailability, longer shelf life, and more efficient delivery methods such as inhaled or controlled-release therapies.

United Therapeutics is not a random partner. The company, founded by CEO Martine Rothblatt to find a cure for her daughter's pulmonary arterial hypertension, already holds a dominant commercial position in rare pulmonary disease and fibrosis treatments. That gives the collaboration a direct path from orbital experiment to an existing clinical pipeline. Rothblatt, speaking at the Beyond Earth Symposium in February, said the ability to produce new molecular shapes in orbit "opens up billions of dollars in markets," and that Varda's routinized launch-and-control model removed the logistical friction that had made International Space Station research impractical for pharmaceutical development.

Bruey framed the deal as "completing the bridge from microgravity science to patient benefit on Earth." Radocea said the collaboration combines United Therapeutics' drug-development expertise with Varda's ability to run processes unavailable under terrestrial conditions. The companies did not disclose financial terms or a timeline for the first orbital drug studies.

If the early missions produce viable new formulations for life-threatening lung diseases, the addressable market extends well beyond rare pulmonary conditions into any drug whose performance is limited by crystal structure.

What the job listings reveal

Varda's careers page lists roughly 89 open roles, split across autonomous systems, propulsion, avionics, mechanical engineering, biologics, and mission operations. That number alone signals something unusual: a space company hiring nearly as heavily on the pharma side as the engineering side.

The breakdown tells the story more clearly. On Zero G Talent's board, Varda added 19 roles in the past week, a pace that puts it in the same hiring tier as much larger aerospace firms. The new listings cluster in a few telling areas.

Spacecraft software dominates. Varda's autonomous systems department alone lists 12 open roles: senior and principal guidance, navigation, and controls engineers, plus a stack of embedded, flight, ground systems, and mission systems software positions. The salary ranges are specific on Zero G Talent's listings:

These are not entry-level satellite jobs. Varda needs engineers who can write fault-tolerant code for vehicles that operate without real-time ground intervention during reentry.

The pharma pipeline is staffed in parallel. The Product and Payload & Mechanisms departments list roles like Scientist, Biologics Formulation; Senior Scientist, Analytical Sciences; Research Associate, Biologics Formulation; and a Director of Mechanisms Engineering for pharmaceutical payloads. There's also a dedicated Process Engineer role on the pharmaceutical team. These aren't lab support; they're the people deciding which proteins get sent to orbit and designing the crystallization hardware that runs inside the capsule.

Manufacturing is scaling on the ground. Varda lists Manufacturing Engineer roles across structures, avionics/electromechanical/harnessing, and integration, plus technicians for propulsion and harness integration. The company is hiring the people who will build W-Series capsules at volume, not just prototype them. A Senior Prototype Machinist role rounds out the list, suggesting some one-off fabrication work still happens in-house.

Propulsion and reentry hardware remain core. A Director of Propulsion Engineering, Manager of Propulsion Systems, and multiple ground fluids propulsion engineers are open. So are a Senior Thermal Analysis Engineer and an Aerodynamics and Flight Mechanics Engineer, roles tied directly to the C-PICA heatshield and reentry profile that Varda has now proven six times.

The internships match the pattern: flight software (C++), GNC, mission operations, mechanical engineering, automation and test, vehicle integration and test. Varda is building a pipeline that feeds both the spacecraft and pharma sides.

Most space companies hire for structures, avionics, and software. Most biotech companies hire for formulation, analytics, and process engineering. Varda needs both, working on the same product line. The orbital-manufacturing workforce isn't a single discipline; it's the overlap between reentry-vehicle engineering and pharmaceutical process development, and the job listings show the company staffing both halves simultaneously.

The workforce inflection behind the funding

Varda does not exist in a vacuum. Orbital pharmaceutical manufacturing is one node in a broader in-space economy that now encompasses roughly 1,000 commercial entities across 1,099 tracked entries, according to Erik Kulu's 2025 survey presented at the International Astronautical Congress. In-space manufacturing is the single most popular category in that database, with 209 entries, and cargo transportation and reentry vehicles follows at 98. About a third of entities are in active or demonstrated status, up from a fraction two years earlier.

The U.S. space economy employed over 373,000 private-sector workers in 2023, the Bureau of Economic Analysis reported in September 2025, and 56 percent of those jobs were STEM occupations — more than double the rate across the overall U.S. workforce. Software developers are the single largest occupation in the space economy. The Census Bureau's Quarterly Workforce Indicators, released at the national-industry level for the first time in January 2026, show that nearly half of all new hires in the space economy cluster were under age 35 in 2024, and the share of young new hires has grown 32 percent over the past decade.

That is the talent pool Varda, Redwire's SpaceMD, and every other orbital manufacturing startup is fishing in, and the pool is not deep enough. A SpaceCom panel in January 2025, covered by SpaceNews, identified the lack of standardized career pathways as a structural hiring obstacle. Joseph Horvath, CEO of training provider Nova Space, compared the gap to the early days of IT certifications: the industry has not agreed on what competencies mean or how to credential them. Tom Cooke, CEO of the freelance aerospace marketplace Spacely, added that the space sector is now competing for the same AI and data-science talent that every other industry wants, and that STEM-degree pipelines are too slow to respond.

The compensation pressure is real. Cooke cited Netflix's revenue per employee at $2.5 million versus Lockheed Martin's $585,000 as a benchmark for how work systems differ across industries bidding for the same engineers. In Colorado, the median aerospace salary is $110,000, but the income needed to buy a home in Denver is $170,000.

Varda's Series C and its 19 open roles on Zero G Talent place it in the upper tier of funded in-space manufacturing ventures. Kulu's database shows Varda among the better-capitalized entrants in the reentry-vehicle segment, alongside Impulse Space at $300 million and Firefly's $868 million IPO. Redwire, which launched its SpaceMD subsidiary for orbital pharma in August 2025, is a publicly traded competitor with NASA and ESA contracts in its base. The Exploration Company, ATMOS Space Cargo, and Inversion Space are all developing reentry capsules that could serve pharmaceutical downmass if the unit economics close.

DARPA's 10-year lunar architecture study, whose results were published in the Commercial Lunar Economy Field Guide in 2025, positions in-space manufacturing as a core capability alongside surface power and excavation. Varda's microgravity biologics work is the orbital counterpart, proving that the same industrial logic applies in LEO before anyone commits to a lunar factory.

The workforce signal is clear: orbital manufacturing is hiring, and it needs people who can write flight software, operate ground systems, navigate FAA reentry licensing, and run crystallization experiments that translate from benchtop to capsule. The jobs are real, the capital is real, and the competition for the people who can do them is just starting.

Working in frontier tech? Zero G Talent tracks the openings: browse frontier tech jobs, openings at NASA and Varda Space, and the people building the field.